Results 281 to 290 of about 824,404 (357)

The peers expanding engagement in stimulant harm reduction with contingency management study: a protocol paper. [PDF]

Addict Sci Clin Pract
Cooke A, Stack E, Peng L, Cook R, Hartzler B, Leichtling G, Hildebran C, Leahy JM, Payne KS, Kunkel LE, Hoffman K, Korthuis PT.   +11 more
europepmc   +1 more source

Tryptophan metabolite atlas uncovers organ, age, and sex‐specific variations

FEBS Open Bio, EarlyView.
Tryptophan metabolites were analyzed across twelve organs, the central nervous system, and serum in male and female mice at three life stages. We found tissue‐, sex‐, and age‐specific differences, including increased indole‐3‐pyruvate and kynurenine in aging males.
Lizbeth Perez‐Castro, Afshan F. Nawas, Jessica A. Kilgore, Pedro A. S. Nogueira, M.Carmen Lafita‐Navarro, Paul H. Acosta, Roy Garcia, Noelle S. Williams, Maralice Conacci‐Sorrell   +8 more
wiley   +1 more source

Overexpression of CDT1 inhibits cell cycle progression at S phase by interacting with the mini‐chromosome maintenance complex and causes DNA damage

FEBS Open Bio, EarlyView.
CDT1 is an essential protein for DNA replication licensing that loads the MCM complex, the eukaryotic replicative DNA helicase, onto replication origins. Overexpression of CDT1 induces cell cycle arrest at the S phase. Here we showed CDT1 inhibits the progression of replication forks by interacting with the MCM complex, leading to the stalling and ...
Takashi Tsuyama, Nonoka Takayama, Rina Tanaka, Yuuki Arai, Yohko Yamaguchi, Yuko Nawata, Yutaro Azuma, Shusuke Tada   +7 more
wiley   +1 more source

Developing a comprehensive inventory to define harm reduction housing. [PDF]

Harm Reduct J
Zaragoza S, Silcox J, Rapisarda S, Summers C, Case P, To C, Chatterjee A, Walley AY, Komaromy M, Green TC.   +9 more
europepmc   +1 more source

A general model for analysis of linear and hyperbolic enzyme inhibition mechanisms

FEBS Open Bio, EarlyView.
We developed a general enzyme kinetic model that integrates these six basic inhibition mechanism onto a single one. From this model, we deduced a general enzyme kinetic equation that through modulation of simple parameters, γ (the relative inhibitor affinity for two binding sites) and β (the reactivity of the enzyme–substrate–inhibitor complex), is ...
Rafael S. Chagas, Sandro R. Marana
wiley   +1 more source

Harm Reduction Unit of the City of Santo André, São Paulo State, Brazil: An Evaluation

, 2010
Silvia Moreira da Silva, Cássia Baldini Soares, Vilmar Ezequiel dos Santos   +2 more
openalex   +1 more source

HSP70 governs permeability and mechanotransduction in primary human endothelial cells

FEBS Open Bio, EarlyView.
HSP70 chemical inhibition reduces endothelial cell proliferation and increases permeability, the latter supported by normal interendothelial junctional protein distribution. HSP70 also plays a role in shear stress response, a hemodynamic force naturally present in blood vessels and correlated with vessel protection.
Andrea Pinto‐Martinez, Everton G. Melo, Isadora C. B. Pavan, Percíllia V. S. Oliveira, Luiza B. C. T. Coimbra, Thaís L. S. Araujo   +5 more
wiley   +1 more source

Mini-review: Harm reduction strategies among people who intentionally use fentanyl. [PDF]

Addict Behav Rep
Paredes J, Sandhu A, Huo S, Timberlake DS.   +3 more
europepmc   +1 more source

Thrombolytic proteins profiling: High‐throughput activity, selectivity, and resistance assays

FEBS Open Bio, EarlyView.
We present optimized biochemical protocols for evaluating thrombolytic proteins, enabling rapid and robust screening of enzymatic activity, inhibition resistance, and fibrin affinity, stimulation, and selectivity. The outcome translates to key clinical indicators such as biological half‐life and bleeding risk. These assays streamline the development of
Martin Toul, Alan Strunga, Jiri Damborsky, Zbynek Prokop   +3 more
wiley   +1 more source

Advancing Equitable Access to Harm Reduction: Implementation and Early Use of an Outdoor Harm Reduction Vending Machine, Kern County, California, 2023. [PDF]

Public Health Rep
Herrera A.
europepmc   +1 more source